

Colinz

Date: 17-05-2025

To,
Cooperate Relation Department
The BSE LIMITED
1st Floor, Phiroze leejeebhoy Towers,
Dalal Street,
Mumbai-400001

Script Code: 531210

Dear Sir/ Madam,

Sub: Newspaper clipping of the Un-Audited Financial Results pursuant to Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the Quarter on 31st March, 2025.

Please find enclosed herewith Newspaper clippings of Audited Financial Results for the quarter and year ended on **31st March, 2025** published in **FREE PRESS JOURNAL** and **NAVSHAKTI** on **17th May, 2025** in pursuance of Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, which were approved in the Board meeting held on **16th May, 2025**.

Kindly acknowledge the receipt of the same and update in your records.

Thanking you,

Yours faithfully,
For Colinz Laboratories Ltd.,

Dr. Mani L. S.
Director & Company Secretary
Din No : 00825886



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123

* NAY SHAKTI *

Dt. 17/05/2025

मुंबई, शनिवार, दि. १७ मे २०२५

नव शक्ति
marathi.freepressjournal.in



COLINZ LABORATORIES LIMITED

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.
(CIN NO : L24200MH1986PLC041128)

EXTRACTS OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025

S. No.	Particulars	QUARTER ENDED			YEAR ENDED	
		Audited	Audited	Un-Audited	Audited	
		31-Mar-25	31-Mar-24	31-Dec-24	31-Mar-25	31-Mar-24
1	Revenue from Operations	152.70	173.64	154.39	682.56	730.46
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items).	12.32	18.96	10.33	61.94	65.03
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	12.32	18.96	10.33	61.94	65.03
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	15.04	13.60	5.33	49.66	48.67
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income(Net of Tax).	19.57	19.78	(6.78)	52.55	80.97
6	Equity Share Capital (Face Value of Rs. 10/- each)	251.91	251.91	251.91	251.91	251.91
7	Earning Per Share (Face value of Rs. 10/- each) (not annualised) (in Rs.)					
	1) Basic	0.60	0.54	0.21	1.97	1.93
	2) Diluted	0.60	0.54	0.21	1.97	1.93

NOTES :-

- 1) The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 16th May, 2025.
- 2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-ll.in.
- 3) The above results of the Company have been audited by the Statutory Auditors and they have issued an unqualified audit opinion on the same.
- 4) Previous figures have been regrouped/ rearranged / reclassified, wherever necessary.

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128
Dr. MANI L. S.
(Chairman of the Meeting)

MUMBAI.
16th May, 2025.



* FREE PRESS JOURNAL *

DI-17/05/2025

10 | THE FREE PRESS JOURNAL | Mumbai, Saturday, May 17, 2025

COLINZ LABORATORIES LIMITED

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078.
(CIN NO : L24200MH1986PLC041128)

EXTRACTS OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025

S. No.	Particulars	QUARTER ENDED			YEAR ENDED	
		Audited	Audited	Un-Audited	Audited	
		31-Mar-25	31-Mar-24	31-Dec-24	31-Mar-25	31-Mar-24
1	Revenue from Operations	152.70	173.64	154.39	682.56	730.46
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items).	12.32	18.96	10.33	61.94	65.03
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	12.32	18.96	10.33	61.94	65.03
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	15.04	13.60	5.33	49.66	48.67
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (Net of Tax).	19.57	19.78	(6.78)	52.55	80.97
6	Equity Share Capital (Face Value of Rs. 10/- each)	251.91	251.91	251.91	251.91	251.91
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.)					
	1) Basic	0.60	0.54	0.21	1.97	1.93
	2) Diluted	0.60	0.54	0.21	1.97	1.93

NOTES :-

- 1) The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 16th May, 2025.
- 2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cll.in.
- 3) The above results of the Company have been audited by the Statutory Auditors and they have issued an unqualified audit opinion on the same.
- 4) Previous figures have been regrouped/rearranged/reclassified, wherever necessary.

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128
Dr. MANI L. S.
(Chairman of the Meeting)

MUMBAI.
16th May, 2025.

